Vertex Pharmaceuticals (NQ:VRTX)

501.15 -2.35 (-0.47%)

Delayed Quote Updated: 10:08 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down

October 05, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

Via StockStory

Topics Energy

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 04, 2026

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.

Via The Motley Fool

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 01, 2026

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward...

Via The Motley Fool

Topics Intellectual Property

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. ↗

September 29, 2026

This biotech player is firing on all cylinders.

Via The Motley Fool

Topics Intellectual Property

2 Healthcare Stocks to Target This Week and 1 We Avoid

September 28, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Via StockStory

2 Healthcare Stocks That Just Delivered Great News for Investors ↗

September 26, 2026

And there could be more positive developments ahead.

Via The Motley Fool

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Via The Motley Fool

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

September 22, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗

September 20, 2026

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Via The Motley Fool

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? ↗

September 18, 2026

This company has had plenty of setbacks in recent years, but it generally bounces back.

Via The Motley Fool

2 Reasons to Like VRTX (and 1 Not So Much)

September 18, 2026

Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13....

Via StockStory

Topics Stocks

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗

September 17, 2026

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Via The Motley Fool

My Top 5 Favorite Stocks for an Uncertain Market ↗

September 16, 2026

These players offer a certain level of stability in any market environment.

Via The Motley Fool

Topics Artificial Intelligence Economy Intellectual Property

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

September 15, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead ↗

September 14, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s...

Via MarketBeat

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 14, 2026

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Via The Motley Fool

September 14, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis ↗

September 12, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a...

Via MarketBeat

Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference ↗

September 12, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal...

Via MarketBeat

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock ↗

September 08, 2026

The company has tremendous prospects.

Via The Motley Fool

Topics Intellectual Property

Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗

September 08, 2026

The company had fallen out of investor favor; its recovery was impressive.

Via The Motley Fool

Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗

September 08, 2026

CRISPR's expanding pipeline could unlock significantly more value by 2031.

Via The Motley Fool

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

September 08, 2026

A look at the three approaches competing to help beta cell replacement survive the immune system

From Biotech Insider

Via GlobeNewswire

3 Market-Beating Stocks for Long-Term Investors

September 08, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

Via StockStory

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Via The Motley Fool

Topics Intellectual Property

Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

September 04, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals...

Via Benzinga

3 Stocks Whose Competitive Walls Tower Over Nvidia's ↗

September 03, 2026

A solid moat favors revenue growth, and that's good news for investors.

Via The Motley Fool

Topics Artificial Intelligence

2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗

September 02, 2026

We'll know a little more about the company's prospects by the end of the year.

Via The Motley Fool

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

September 01, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.